National Institutes of Health: Esophageal Neoplasms trials

The registry lists 47 Esophageal Neoplasms studies with National Institutes of Health as lead sponsor. 2 are open to participants now and 14 have results posted.

Phase 1 21Phase 2 20Phase 3 1No phase 11(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• The Vanguard Study: Testing a New Way to Screen for CancerRecruitingNCT06995898Not applicable
• Evaluation of Cell Changes in Blood and Tissue in Cancers of the Lung, Esophagus and Lung LiningRecruitingNCT00242723
• Oral Decitabine and Tetrahydrouridine as Epigenetic Priming for Pembrolizumab-Mediated Immune Checkpoint Blockade in Patients With Inoperable, or Unresectable Locally Advanced or Metastatic Non-Small Cell Lung Cancers and Esophageal CarcinomasTerminatedNCT03233724Phase 1/2Results posted
• Metabolomic and BH3 Profiling of Esophageal Cancers: Identification of Novel Assessment Methods of Treatment Response for Precision TherapyTerminatedNCT03223662Phase 2Results posted
• Olaparib and Ramucirumab in Treating Patients With Metastatic or Locally Recurrent Gastric or Gastroesophageal Junction Cancer That Cannot Be Removed by SurgeryCompletedNCT03008278Phase 1/2Results posted
• Continuous 24h Intravenous Infusion of Mithramycin, an Inhibitor of Cancer Stem Cell Signaling, in People With Primary Thoracic Malignancies or Carcinomas, Sarcomas or Germ Cell Neoplasms With Pleuropulmonary MetastasesTerminatedNCT02859415Phase 1/2Results posted
• Metformin Hydrochloride in Preventing Esophageal Cancer in Patients With Barrett EsophagusCompletedNCT01447927Phase 2Results posted
• Predictors of Tumor Response and of Radiation Therapy Side Effects in Patients With Gastrointestinal CancersTerminatedNCT01445327Results posted
• Radiation Therapy, Paclitaxel, and Carboplatin With or Without Trastuzumab in Treating Patients With Esophageal CancerCompletedNCT01196390Phase 3Results posted
• Paclitaxel With or Without Cixutumumab as Second-Line Therapy in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction CancerActive, not recruitingNCT01142388Phase 2Results posted
• Ursodiol in Treating Patients With Barrett Esophagus and Low-Grade DysplasiaCompletedNCT01097304Phase 2Results posted
• A Study of Patients Receiving High-Dose Rate BrachytherapyCompletedNCT00924027Phase 2Results posted
• Saracatinib in Treating Patients With Locally Advanced or Metastatic Stomach or Gastroesophageal Junction CancerCompletedNCT00607594Phase 2Results posted
• Esomeprazole Magnesium With or Without Aspirin in Preventing Esophageal Cancer in Patients With Barrett EsophagusCompletedNCT00474903Phase 2Results posted
• A Phase I/II Study of Oblimersen Plus Cisplatin and Fluorouracil in Gastric & Esophageal Junction CancerTerminatedNCT00064259Phase 1/2Results posted
• Bortezomib With or Without Irinotecan in Treating Patients With Cancer of the Gastroesophageal Junction or StomachCompletedNCT00061932Phase 2Results posted
• Phase I/II Evaluation of a Cancer Lysate Vaccine and Montanide(R) ISA-51 VG With Entinostat and Nivolumab as Adjuvant Therapy Following Chemoradiation Therapy With or Without Surgery for Locally Advanced Esophageal CancerWithdrawnNCT05898828Phase 1/2
• National Cancer Institute "Cancer Moonshot Biobank"Active, not recruitingNCT04314401
• Nivolumab or Expectant Observation Following Ipilimumab, Nivolumab, and Surgery in Treating Patients With High Risk Localized, Locoregionally Advanced, or Recurrent Mucosal MelanomaWithdrawnNCT03220009Phase 2
• Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)Active, not recruitingNCT02465060Phase 2
• Ropidoxuridine in Treating Patients With Advanced Gastrointestinal Cancer Undergoing Radiation TherapyActive, not recruitingNCT02381561Phase 1
• Akt Inhibitor MK2206, Lapatinib Ditosylate, and Trastuzumab in Treating Patients With Locally Advanced or Metastatic HER2-Positive Breast , Gastric, or Gastroesophageal Cancer That Cannot Be Removed By SurgeryTerminatedNCT01705340Phase 1
• Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney DysfunctionActive, not recruitingNCT01366144Phase 1
• Tumor Cell Vaccines With ISCOMATRIX Adjuvant and Celecoxib in Patients Undergoing Resection of Lung and Esophageal Cancers and Malignant Pleural MesotheliomasTerminatedNCT01258868Phase 1
• Pilot Study of Allogeneic Tumor Cell Vaccine With Metronomic Oral Cyclophosphamide and Celecoxib in Patients Undergoing Resection of Lung and Esophageal Cancers, Thymic Neoplasms, and Malignant Pleural MesotheliomasTerminatedNCT01143545Phase 1
• Esophageal Cancer in Northeastern IranCompletedNCT00450788
• Erlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Neck Cancer, Non-Small Cell Lung Cancer, or Colorectal CancerCompletedNCT00397384Phase 1
• Nutrition Intervention Trials in Linxian Follow-up StudyCompletedNCT00342654
• Environmental and Biological Monitoring Pilot Study for Polycyclic Aromatic Hydrocarbons in Linxian, ChinaCompletedNCT00342472
• Early Detection of Esophageal CancerTerminatedNCT00341523
• Esophageal Cancer Genetics StudiesCompletedNCT00341276
• Stomach and Esophageal Cancers in Northern IranCompletedNCT00339742
• FR901228 in Treating Patients With Refractory Stomach Cancer or Gastroesophageal Junction CancerTerminatedNCT00098527Phase 2
• Depsipeptide/Flavopiridol Infusion for Cancers of the Lungs, Esophagus, Pleura, Thymus or MediastinumTerminatedNCT00094978Phase 1
• 3-AP Plus Cisplatin in Treating Patients With Recurrent or Metastatic Adenocarcinoma of the Esophagus or Gastroesophageal JunctionCompletedNCT00077545Phase 2
• Arsenic Trioxide in Treating Patients With Advanced Cancer of the Esophagus or Gastroesophageal JunctionTerminatedNCT00061958Phase 2
• Erlotinib Hydrochloride in Treating Patients With Advanced Esophageal Cancer or Stomach CancerCompletedNCT00045526Phase 2
• 7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007)CompletedNCT00031681Phase 1
• Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney DysfunctionCompletedNCT00030498Phase 1
• Epirubicin, Carboplatin, and Capecitabine in Treating Patients With Unresectable Locally Advanced, Metastatic, or Recurrent Solid TumorCompletedNCT00021047Phase 1/2
• Decitabine in Treating Patients With Unresectable Lung or Esophageal Cancer or Malignant Mesothelioma of the PleuraCompletedNCT00019825Phase 1
• Combination Chemotherapy in Treating Patients With Recurrent, Refractory, or Metastatic Solid Tumors or LymphomasCompletedNCT00019513Phase 1
• LMB-9 Immunotoxin in Treating Patients With Advanced Solid TumorsCompletedNCT00019435Phase 1
• Vaccine Therapy in Treating Patients With Advanced or Recurrent CancerCompletedNCT00019110Phase 1
• Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/NeuCompletedNCT00004074Phase 1
• Topotecan and Radiation Therapy in Treating Patients With Solid Tumors or LymphomaCompletedNCT00002625Phase 1
• The Effects of Upper Airway and Digestive Tract Tumors on the Immune SystemCompletedNCT00001603